comparemela.com

Kevin Norrett News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Codexis, Inc (NASDAQ:CDXS) Q4 2023 Earnings Call Transcript

Codexis, Inc. beats earnings expectations. Reported EPS is $-0.1, expectations were $-0.16.

Dan ariasKayla hostetlerCarrie mckimStefan lutzJohn maraganoreKevin norrettMasad damhaEvan stamplerJim lalondeBrandon couillardSynthesis innovation labCodexis incExchange commissionNestle health scienceAlnylam pharmaceuticalsInnovation lab

Aldevron to acquire license to Codex HiCap RNA Polymerase

Aldevron has signed an agreement with US-based enzyme engineering company Codexis to acquire global exclusive license to Codex HiCap RNA Polymerase.

Tom fotiKevin norrettCodex hicap

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

North dakotaUnited statesLauren mustoTom fotiCarrie mckimEllen shaferKevin norrettSecurities exchangeCodexis incExchange commissionAldevron enter exclusive licensing agreementChief operating officerProtein businessSecurities actSecurities exchange actCodexi annual report

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase

Codexis and Aldevron Enter Exclusive Licensing Agreement for Codex® HiCap RNA Polymerase
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

North dakotaUnited statesContactlauren mustoKevin norrettTom fotiContactellen shaferCodexis contactsinvestor contactcarrie mckimCodexis incExchange commissionSecurities exchangeDanaher corporationCodexi codexChief operating officerProtein businessForward looking statementsthisSecurities act

Codexis KOL Event Highlights Significant Need for an Enzymatic Route of Synthesis in RNAi Therapeutics Manufacturing

REDWOOD CITY, Calif., Dec. 11, 2023 Codexis, Inc. , a leading enzyme engineering company, hosted a virtual Key Opinion Leader event on Friday, December 8, 2023, to discuss the growth of RNA.

Kevin norrettCarrie mckimStefan lutzLauren mustoJohn maraganoreDavid butlerCodexis incHongene biotech corporationSecurities exchangeExchange commissionGlobenewswire incAlnylam pharmaceuticalsCompany enzymeKey opinion leaderEnzyme catalyzed oligonucleotideFormer chief executive officer

vimarsana © 2020. All Rights Reserved.